11 Results for "

mouse RIPK1

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "mouse RIPK1" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-P704200
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RIPK1; Receptor-Interacting Protein Kinase 1; Receptor Interacting Serine/Threonine Kinase 1; Receptor-Interacting Protein 1; RIP-1; Cell Death Protein RIP; RIP1; Serine/Threonine-Protein Kinase RIP; RIP; AIEFL; Receptor (TNFRSF)-Interacting Serine-Threon
Species:  
Mouse
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-RS11993
Research Areas:  

Others

Ripk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ripk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-148239
CAS No.: 2095514-84-2
Purity:  98.32%
TP-030-2, a chemical probe, is a RIPK1 inhibitor (human Ki=0.43 nM; mouse IC50=100 nM) .
loading...
    loading...
Cat. No.: HY-156367
CAS No.: 2561431-77-2
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK1-IN-16 is an orally active and potent inhibitor of RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK1-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis .
loading...
    loading...
Cat. No.: HY-144277
CAS No.: 2173556-92-6
Target:  

RIP kinase Necroptosis

Research Areas:  

Inflammation/Immunology

RIPK1-IN-12 is a potent RIPK1 inhibitor. RIPK1-IN-12 inhibits necroptosis in both human and mouse cells, with EC50 values of 1.6 and 2.9 nM, respectively .
loading...
    loading...
Cat. No.: HY-144276
CAS No.: 2173557-02-1
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK1-IN-11 is a potent and orally active RIPK1 inhibitor (Kd=9.2 nM; IC50=67 nM). RIPK1-IN-11 inhibits necroptosis in both human and mouse cells (EC50=17-30 nM). Anti-inflammatory activity .
loading...
    loading...
Cat. No.: HY-156920
CAS No.: 158983-23-4
Target:  

Necroptosis RIP kinase

Research Areas:  

Inflammation/Immunology Cancer

VDX-111 is an analog of vitamin D. VDX-111 exhibits cytotoxicity in ovarian cancer cells through upregulation of RIPK1/RIPK3 pathway and induction of necroptosis. VDX-111 promotes expressions of cytokines and exhibits antitumor activity in mouse model .
loading...
    loading...
Cat. No.: HY-168770
CAS No.: 862377-51-3
Research Areas:  

Cardiovascular Disease

Cl-Necrostatin-1 is a RIPK1 inhibitor. Cl-Necrostatin-1 can also inhibit TNF-α-induced necroptosis in Jurkat cells deficient in Fas-associated death domain protein (FADD; EC50 = 180 nM), a modification that prevents caspase activation in response to death-domain receptor signaling. Cl-Necrostatin-1 can also reduce infarct size in a mouse model of middle cerebral artery occlusion (MCAO). Cl-Necrostatin-1 is used for research in cardiovascular and cerebrovascular diseases .
loading...
    loading...
Cat. No.: HY-P10977
Research Areas:  

Neurological Disease

Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease .
loading...
    loading...
Cat. No.: HY-183781
Target:  

RIP kinase Necroptosis

Research Areas:  

Inflammation/Immunology

RIPK1-IN-41 is an orally active RIPK1 inhibitor with an IC50 of 92 nM and a KD of 106.8 nM. RIPK1-IN-41 reduces the phosphorylation level of RIPK1, inhibits necrosome formation, blocks the activation of RIPK3 and MLKL, maintains mitochondrial and lysosomal functions, preserves cell membrane integrity, and suppresses necroptosis. RIPK1-IN-41 alleviates hypothermia and multi-organ damage in a mouse model of systemic inflammatory response syndrome induced by mTNF-α. RIPK1-IN-41 is applicable to research related to systemic inflammatory response syndrome .
loading...
    loading...
Cat. No.: HY-181596
WJH-C19 is an orally active RIPK1 inhibitor with an IC50 of 5.7 nM. WJH-C19 inhibits the RIPK1/RIPK3/MLKL signaling axis, blocks RIPK1 phosphorylation, suppresses the phosphorylation of downstream RIPK3 and MLKL, disrupts necrosome formation, and exhibits protective effects against necroptosis (Apoptosis) in multiple cell lines. WJH-C19 ameliorates symptoms of inflammatory bowel disease in a mouse colitis model by regulating the necroptosis pathway. WJH-C19 alleviates inflammation and bone destruction in a mouse model of rheumatoid arthritis. WJH-C19 is applicable to research related to inflammatory bowel disease and rheumatoid arthritis .
loading...
    loading...
  • 1